Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020

Affiliations

• ¹ Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, Department of Internal Medicine, New York, NY, USA.
• ² University of Utah, Huntsman Cancer Center, Division of Hematology, Salt Lake City, Utah, USA.
• ³ University of Kansas, University of Kansas School of Medicine, Kansas City, Kansas, USA.
• ⁴ Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
• ⁵ Division of Blood and Marrow Transplantation, University of California San Diego, San Diego, CA, USA.
• ⁶ Department of Hematology, Columbia University, New York, NY, USA.
• ⁷ Division of Hematology/Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
• ⁸ University of Utah, Huntsman Cancer Center, Division of Hematology, Salt Lake City, Utah, USA. g.mohyuddin@hci.utah.edu.